Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRN7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $33,168.26 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The contract carries no set-aside designation, reflecting the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.99 billion ceiling value and an ultimate completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, supporting military medical facilities worldwide through its comprehensive product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The PPV-G GEN V initiative represents a $30.3 billion federal acquisition strategy designed to streamline pharmaceutical supply chain management across the military healthcare system. The delivery order has an ultimate completion date of January 5, 2026, with place of performance in Park Ridge, Illinois, positioning this award as part of the company's recurring role in fulfilling specialized pharmaceutical requirements for DoD medical operations.
Quick answers
Who was awarded contract SPE2DR26FCRN7?
SPE2DR26FCRN7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FCRN7 worth?
The government has obligated $33,168 on SPE2DR26FCRN7.
Is contract SPE2DR26FCRN7 an order under another contract?
Yes. SPE2DR26FCRN7 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRN7 competed?
The extent of competition for SPE2DR26FCRN7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award